JP2024543209A - インターロイキン-2剤の使用方法 - Google Patents

インターロイキン-2剤の使用方法 Download PDF

Info

Publication number
JP2024543209A
JP2024543209A JP2024532776A JP2024532776A JP2024543209A JP 2024543209 A JP2024543209 A JP 2024543209A JP 2024532776 A JP2024532776 A JP 2024532776A JP 2024532776 A JP2024532776 A JP 2024532776A JP 2024543209 A JP2024543209 A JP 2024543209A
Authority
JP
Japan
Prior art keywords
amino acid
seq
fold
fusion protein
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543209A5 (https=
JPWO2023102463A5 (https=
Inventor
グレゴリー バブコック,
ウェイン ハンコック,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of JP2024543209A publication Critical patent/JP2024543209A/ja
Publication of JP2024543209A5 publication Critical patent/JP2024543209A5/ja
Publication of JPWO2023102463A5 publication Critical patent/JPWO2023102463A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024532776A 2021-12-01 2022-12-01 インターロイキン-2剤の使用方法 Pending JP2024543209A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163284978P 2021-12-01 2021-12-01
US63/284,978 2021-12-01
US202263348201P 2022-06-02 2022-06-02
US63/348,201 2022-06-02
PCT/US2022/080728 WO2023102463A1 (en) 2021-12-01 2022-12-01 Methods of using interleukin-2 agents

Publications (3)

Publication Number Publication Date
JP2024543209A true JP2024543209A (ja) 2024-11-19
JP2024543209A5 JP2024543209A5 (https=) 2025-12-08
JPWO2023102463A5 JPWO2023102463A5 (https=) 2025-12-08

Family

ID=84981477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532776A Pending JP2024543209A (ja) 2021-12-01 2022-12-01 インターロイキン-2剤の使用方法

Country Status (10)

Country Link
US (1) US20240041981A1 (https=)
EP (1) EP4440598A1 (https=)
JP (1) JP2024543209A (https=)
KR (1) KR20250169356A (https=)
CN (1) CN120131911A (https=)
AU (1) AU2022399832A1 (https=)
CA (1) CA3238574A1 (https=)
MX (1) MX2024006746A (https=)
TW (1) TW202333772A (https=)
WO (1) WO2023102463A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
WO2025221954A1 (en) * 2024-04-17 2025-10-23 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
CN119638850A (zh) * 2024-11-07 2025-03-18 浙江大学 双特异性细胞因子融合蛋白及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
PH12017501856B1 (en) * 2015-04-10 2022-08-10 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
KR102687530B1 (ko) 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
US20210017247A1 (en) * 2017-07-03 2021-01-21 Torque Therapeutics, Inc. Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
KR20250169356A (ko) 2025-12-03
CA3238574A1 (en) 2023-06-08
CN120131911A (zh) 2025-06-13
WO2023102463A1 (en) 2023-06-08
TW202333772A (zh) 2023-09-01
US20240041981A1 (en) 2024-02-08
EP4440598A1 (en) 2024-10-09
AU2022399832A1 (en) 2024-06-06
MX2024006746A (es) 2024-08-09

Similar Documents

Publication Publication Date Title
JP7516254B2 (ja) Il-15/il-15raヘテロ二量体fc融合タンパク質およびその使用
JP7850199B2 (ja) インターロイキン-2作用物質およびその使用
JP2024543209A (ja) インターロイキン-2剤の使用方法
JP6703520B2 (ja) Cd3イプシロンおよびbcmaに対する二特異性抗体
KR100959248B1 (ko) 사람형 cdr-이식 항체 및 이의 항체 단편
US20140193408A1 (en) Soluble proteins for use as therapeutics
JP2021502826A (ja) Dドメイン含有ポリペプチドおよびその使用
CN107428839A (zh) 针对CD3ε和BCMA的双特异性抗体
KR102204127B1 (ko) 항-cd83 항체 및 이의 용도
RS66234B1 (sr) Anti-ccr8 antitela
KR20230129018A (ko) 인터류킨-2 작용제를 사용하는 방법
JP2024503506A (ja) インターロイキン-2変異体およびその使用
US20250353908A1 (en) D-domain containing polypeptides and uses thereof
KR20230166120A (ko) 새로운 tnfr2 결합 분자
CN114867751B (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
CN117255807A (zh) 与NKp46和CD123结合的多功能自然杀伤(NK)细胞接合器
CN118871123A (zh) 使用白细胞介素-2药剂的方法
HK40128460A (zh) 使用白细胞介素-2药剂的方法
HK40111234A (zh) 使用白细胞介素-2药剂的方法
HK40101528A (zh) 结合至cd20、nkp46、cd16并缀合至il-2的多特异性抗体
EA053031B1 (ru) Усеченный полипептид taci и его слитый белок и применение
CN116997351A (zh) 白介素-2突变体及其用途
CN118201631A (zh) 使用白介素-2制剂的方法
HK40078517A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251128